EUVIMEDEUVIMED entdecken
CrossrefInfokarte

An interpretable multi‐task whole‐slide histopathology AI model for non‐small cell lung cancer: Cross‐cohort generalisation, spatial attention–transcriptomic integration, and molecular–immune profiling

Renyi Lu, Anqi Lin, Aimin Jiang, Yuying Feng, Xiuhui Fang, Junyi Shen, Yifeng Bai, Shengkun Peng, Jian Zhang, Quan Cheng, Suyin Feng, Qinglin Li, Peng Luo

Clinical and Translational Medicine · 2026-07 · 16 (7)

DOI: 10.1002/ctm2.70744 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Tumour‐node‐metastasis staging does not fully explain prognostic heterogeneity in non‐small cell lung cancer. We evaluated whether haematoxylin‐and‐eosin whole‐slide images could estimate histological subtype, pathological stage probabilities, survival risk and spatially grounded biological associations. Methods SparseAGE‐MTL, a weakly supervised multi‐task multiple‐instance learning model with a shared projection‐topology encoder and endpoint‐specific heads, was trained and benchmarked in 954 The Cancer Genome Atlas cases using seven pathology feature spaces and 18 comparator models. External evaluation used 948 tissue‐microarray and 324 whole‐slide cases. Attention maps were co‐registered with 10x Visium spatial transcriptomics and integrated with bulk transcriptomics, immune‐infiltration estimates and ESTIMATE scores. Analyses included paired model comparisons, false‐discovery‐rate correction, Cox models, calibration assessment and decision curve analysis. Results In the CONCH feature space, SparseAGE‐MTL achieved 93.73% accuracy, 98.19% area under the receiver‐operating‐characteristic curve and 93.08% F1‐score for adenocarcinoma/squamous cell carcinoma classification in internal benchmarking; external area‐under‐the‐curve values were approximately .91 and .82. Stage estimation had lower discrimination, with external overall area under the curve approximately .70 and cohort‐dependent calibration. Risk‐score‐defined groups differed in overall survival in both histological subtypes and showed similar external trends. High‐attention regions were enriched at tumour–stroma or tumour–immune interfaces and were associated with B‐cell, fibroblast, C1QC, COL1A1, epithelial–mesenchymal transition, metastasis and hypoxia signals. Higher risk cases showed malignant pathway activation, lower immune/stromal scores, higher tumour purity and subtype‐specific immune/stromal differences. Adding the risk score to the clinical model increased external pooled concordance index from approximately .620 to .672. Conclusions In retrospective cohorts, SparseAGE‐MTL generated subtype‐classification, stage‐probability and survival‐risk outputs from routine pathology images. Subtype classification had higher numerical performance than stage estimation. Survival‐risk and attention outputs were associated with outcome and spatial/transcriptomic features, but prospective, treatment‐annotated validation is required before clinical use. Key points SparseAGE‐MTL is a weakly supervised multi‐task MIL framework that jointly performs NSCLC subtype classification, stage prediction, and survival risk estimation from routine H&E slides using only slide-level labels. The model achieves stable competitive performance across seven feature spaces and 18 comparators, with external validation demonstrating robust generalization to independent WSI and TMA cohorts. Attention hotspots co‐localize with tumor‐stroma/immune interfaces and spatial transcriptomic signatures of EMT, hypoxia, and C1QC/COL1A1 enrichment, providing biologically grounded interpretability. High‐risk groups exhibit activated malignant pathways, lower immune/stromal scores, higher tumor purity, and incremental prognostic value beyond clinical variables.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →